The FDA on March 20, 2018 approved ADCETRIS® to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy. ADCETRIS® is a product of Seattle Genetics, Inc.
Bottom Ad
Advertisement
Subscribe
